Author

Raed A Alroughani

Amiri Hospital - Cited by 6,038 - Neurology - Multiple Sclerosis - Epidemiology

Biography

He is affiliated to Division of Neurology, Amiri Hospital, Sharq, Kuwait, Neurology Clinic, Dasman Diabetes Institute, Dasman, Kuwait. He is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals
Title
Cited by
Year
Diagnosis and classification of optic neuritis
A Petzold, CL Fraser, M Abegg, R Alroughani, D Alshowaeir, R Alvarenga, ...The Lancet Neurology 21 (12), 1120-11, 2022202
34
2022
Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severity
S Simpson-Yap, A Pirmani, T Kalincik, E De Brouwer, L Geys, T Parciak, ...Neurology-Neuroimmunology Neuroinflammation 9 (6), 2022202
14
2022
Risk factors of white matter hyperintensities in migraine patients
JY Al-Hashel, R Alroughani, K Gad, L Al-Sarraf, SF AhmedBMC neurology 22 (1), 1-9, 2022202
5
2022
Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis
I Roos, C Malpas, E Leray, R Casey, D Horakova, EK Havrdova, ...Neurology 99 (17), e1926-e1944, 2022202
5
2022
Family planning considerations in people with multiple sclerosis
KM Krysko, R Dobson, R Alroughani, MP Amato, R Bove, AI Ciplea, ...The Lancet Neurology 22 (), 350-366, 2023202
4
2023
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network
A Signori, J Lorscheider, S Vukusic, M Trojano, P Iaffaldano, J Hillert, ...Journal of Neurology, Neurosurgery & Psychiatry 9 (1), 23-30, 2023202
4
2023
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
S Simpson-Yap, A Pirmani, E De Brouwer, LM Peeters, L Geys, T Parciak, ...Multiple Sclerosis and Related Disorders 66, 10072, 2022202
4
2022
Comparative effectiveness in multiple sclerosis: A methodological comparison
I Roos, I Diouf, S Sharmin, D Horakova, EK Havrdova, F Patti, ...Multiple Sclerosis Journal 9 (3), 36-33, 030
2
2023
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
T Spelman, S Ozakbas, R Alroughani, M Terzi, S Hodgkinson, G Laureys, ...Multiple Sclerosis Journal 9 (), 1-35, 030
2
2023
A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis
I Roos, S Hughes, G MacDonnell, C Boz, R Alroughani, S Ozakbas, ...MULTIPLE SCLEROSIS JOURNAL 8 (3_ SUPPL), 951-953, 0
2
2022
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
I Roos, S Hughes, G McDonnell, CB Malpas, S Sharmin, C Boz, ...JAMA neurology, 2023202
1
2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity
T Spelman, D Horakova, S Ozakbas, R Alroughani, M Onofrj, T Kalincik, ...Multiple Sclerosis and Related Disorders 70, 04477, 2023202
1
2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
T Kalincik, S Sharmin, I Roos, MS Freedman, H Atkins, J Burman, ...JAMA Neurology, 2023202
1
2023
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
C Zhu, Z Zhou, I Roos, D Merlo, T Kalincik, S Ozakbas, O Skibina, J Kuhle, ...Journal of Neurology, Neurosurgery & Psychiatry 93 (2), 330-337, 2022202
1
2022

Referred From: https://scholar.google.com.my/citations?user=dwIorsYAAAAJ&hl=en

Cited by
Citations 6038
h-index 40
i10-index 111
Recommended Journals
Open Access Journals